Medical Isotope Production by Electron Accelerators. R.S. Orr University of Toronto
|
|
|
- Dylan Daniel
- 6 years ago
- Views:
Transcription
1 Medical Isotope Production by Electron Accelerators R.S. Orr University of Toronto
2 Power Reactor Uranium Fission Chain reaction neutrons
3 ANSTO's Open Pool Australian Lightwater (OPAL) Reactor is a state-of-the-art 20 Megawatt reactor that uses low enriched uranium fuel and is cooled by water.
4
5 First Fuel Rod View into Reactor Pool
6 Cherenkov Radiation from reactor under power
7 NU Reactor at Chalk River
8
9 Resonant Accelerator Concept Ising , Wideroe Alternating (radio frequency) fields allow higher voltages The acceleration occurs in the electric field between cylindrical drift tubes. The RF power must be synchronised with the motion of the electrons, so that acceleration occurs in every gap. Linear Accelerator = LINAC
10 elinac 1.3 GHz ILC Technology Cornell/Orsay (DC) Coupler TESLA/ILC 9-Cell Cavity ILC Main LINAC Cryomodule
11
12
13 Current Issues in Isotope Production used in 80% of all nuclear medicine procedures. is supplied via generator. is produced by fission of Two major producers AECL NRU reactor (Canada) Covidien HFR reactor (Netherlands)
14 Current Demand In North America US - ~70,000 procedures daily using Canada about 7% of this Half life of is 66 hours, 20% decays each day 6-day curie is unit of measurement Amount available for use after 6 days North America uses ~7,000 6-day-Ci per week World demand is ~ 12,000 6-day-Ci
15 Current Production Process Reactor used to irradiate Highly Enriched Uranium (HEU) target with neutrons Reactor downside HEU weapons proliferation issue Target waste stream Reactor safety issues Reactor licensing Reactor decommissioning
16 Overview of Production Chain
17
18 Time Critical Process
19 Major Producers and Suppliers MDS Nordion (AECL, Canada) 40% (60%) Covidien (Netherlands) 25% (40%) Institut National des Radioélements (Belgium) 20% (0%) Nuclear Technology Products (South Africa) 10% (0%) Australian Nuclear Science & Technology Organization 0 (0)
20 Reactors NRU (Canada) 135 MW, started 1957 HFR (Netherlands) 45 MW, started in 1961 BR2 (Belgium) 100 MW, started 1961 SAFARI (South Afrika) 20MW, started in 1965 Osiris (France) 70 MW, started in 1966 OPAL (Australia) 20 MW, started in 2007
21 Some Facts Most reactors mentioned use Highly Enriched Uranium OPAL uses 25% North American Production need day curies/ week 50% of global demand Most reactors are aging OPAL cannot supply North American needs
22 Reactor In-service date Target uranium enrichment type NRU (Canada) BR2 (Belgium) HFR (Netherlands) SAFARI (South Africa) 1957 HEU 1961 HEU 1963 HEU 1965 HEU
23 Critical Mass of vs Enrichment Level
24 Reactor Reliability Issues NRU shutdown for 3 weeks late May 2008 Heavy water leak return to service 1 st quarter 2010 Canadian government get out of isotope business HFR technical problems in 2008 back in Replacement due BR2 shut down in Fall due to release. OPAL startup delayed to 2008 on power. Osiris replaced by Jules Horowitz 2014 at most 25% of world supply Near term solution is supplying local needs from cyclotrons
25 Canadian Solution MDS-Nordion contracted AECL to construct two reactors. 10 MW HEU principally MAPLE MAPLE Simulations showed power coefficient reactivity 0.12mk/MW Measurement +0.28mk/MW Not understood problem for license Cancelled May 2008 $Millions down the drain..
26 Present Process -Reactor Non HEU Alternatives Reactor Electron Accelerator Electron Accelerator
27 Neutron Capture For a reactor flux of Secular equilibrium after 14 days 2.6 six-day-ci per gm. Low activity cf day-Ci for HEU reactor process Advantage No target waste stream. Disadvantages Major change in technology of separation of two Mo isotopes for generator + low activity High Flux reactor based technique
28 Photo-neutron 50 MeV, 500 kw electron accelerator Bremsstrahlung irradiator Electron beam High Z converter e.g. liquid Hg target
29 Photo-neutron 500 kw accelerator After 14 days 21 six-day-ci per gm. High activity
30 Photo-neutron Advantages No target waste stream. Ease of licensing. Cost and scheduling more predictable for accelerator. Disadvantages Major change in generator technology because of different target. Clinical testing/approval for new product. Cost of target 10% isotope.
31 Giant Dipole Resonance & Photo-fission W.T. Diamond / Nuclear Instruments and Methods in Physics Research A 432 (1999) 471}482
32 Giant Dipole Resonance (GDR) Bremstrahlung and Photofission
33 Yield Comparison Neutron induced Flux of gives fission in reactor: 15kW/gm Aluminum matrix to absorb power. At 6% yield day-Ci per gram. Photo-fission of in an electron accelerator: Assume 50% of energy of 50 MeV machine into photons 0-50MeV. 45% overlap with GDR (10 20 MeV ) concentrated at 15 MeV kW of photons at 15MeV per ma of beam current. γ fission rate/gm of in 50 kw beam is At 6% yield day-Ci per gram. Need about 200 times target material - is cheap.
34 Can We Really Get 6% Yield?
35 Advantages of Accelerator over Reactor Can be quickly turned on and off no consequences. Does not produce radioactive waste from operation. Target waste is similar to reactor solution. Yield is not sensitive to use of LEU or HEU. Proliferation issue. Scalable technology. Additional accelerators can be turned on/off to meet demand. Licensing & decommissioning straightforward.
36 Caveats on Accelerator New technology intrinsically unproven. Substantial R&D e.g. high power target. Irradiated material may not be compatible with existing HEU recover and refinement facilities. Remains to be seen if it is economically competitive.
37 Accelerator Requirements Progress in technology has made high power electron accelerators an economic proposition. Notably super conducting radio frequency cavities. Power efficiency. Compactness. High accelerating gradient. Need several MegaWatts at 100% duty factor. 50 MeV at 100 ma 5 MWatt machine Two frequencies have commercial klystrons etc. 704 MHz 1.3 GHz
38 704MHz Option Based on Brookhaven Energy Recovery LINAC. 100 ma, 704MHz, 140 pc per bunch. Single cryomodule housing 5x5-cell superconducting RF cavities. 10 MeV per cavity 100 ma => 1MW per cavity 2x500kW klystrons. Wall-plug efficiency 40% (klystrons 60%) => 12MW for 2K cavities. 704MHz allows 4K operation of cavities several advantages Reduced complexity, lower operating and capiotal costs. C$60 Million.
39 1.3 GHz Option Scaled version of Cornell 0.5 MW 1.3GHz LINAC. 50x 2-cell cavities driven by 50 klystrons 5 MW 5 cells per cryostat C$125 Million
40 704MHz 704MHz versus 1.3GHz Frequency is in TV broadcast range. Klystrons less specialized than 1.3G Hz. RF structures have large apertures. Reduces wake-field problems. RF input couplers can operate at higher power levels than 1.3 GHz. Fewer components- lower cost + reliability. 4 K operation. 1.3 GHz Synergy with other projects in many Labs. International Linear Collider. Free electron lasers. 3 rd generation light sources.
41 Plans Target E-linac using SRF New 50 MeV electron LINAC funded By Canada Foundation for Innovation Isotope Production Isotopes for Medicine Isotopes for Physics Develop, deploy, & transfer SRF technology to Canadian industry Produce novel isotope beams for nuclear physics and materials science Demonstrate a transformative approach for producing medical isotopes Fission Yield (%) 99 Mo 132 Sn Mass Number
42 elinac
43 elinac Time Evolution
44 Proof of Principle ( )
45 Proof of Principle ( ) Assemble test accelerator system. Based on elinac injection cryomodule (ICM) Fabricate and commission targets with MDS Nordion. Transfer hot target to extraction system. Purify Mo-99 Quality control ICM fabrication in Collaboration with Variable Energy Cyclotron Centre (VECC) in Kolkata
46 Yield of 6-day-Ci vs Energy and Power
47 Target System Target system a challenge Production system 750 kw of γ and fission - 5 converters each followed by 10 targets - 15 kw per target Liquid Hg or water cooled W Proof of Principle (50kW) Power in converter 25kW Power in target 15 kw
48 Conclusion High Power elinacs can be a viable alternative to reactors for the production of
Producing Molybdenum-99 in CANDU Reactors. Jerry M Cuttler Cuttler & Associates Inc. Abstract
31 st Annual Conference of the Canadian Nuclear Society, Montréal, Québec, 2010 May 24-27 Producing Molybdenum-99 in CANDU Reactors Jerry M Cuttler Cuttler & Associates Inc Abstract This paper discusses
The Future of LEU in the Global Mo-99 Supply Chain
The Future of LEU in the Global Mo-99 Supply Chain Ira Goldman, Director, Strategic Product Supply High Country Nuclear Medicine Conference Vail Marriott March 2013 NRU HFR BR2 Osiris LVR-15 LMI Mo-99
HEU MINIMISATION CHALLENGES. THE SUPPLY OF THE MEDICAL ISOTOPE 99-MOLYBDENUM/99m- TECHNETIUM
HEU MINIMISATION CHALLENGES THE SUPPLY OF THE MEDICAL ISOTOPE 99-MOLYBDENUM/99m- TECHNETIUM Chad Westmacott Nuclear Development Division OECD Nuclear Energy Agency 99m Tc is the decay product of 99 Mo
The Current State of Mo-99 Supply and the Conversion to LEU
The Current State of Mo-99 Supply and the Conversion to LEU Target Audience: Pharmacists ACPE#: 0202-0000-18-078-L04-P Activity Type: Knowledge-based Target Audience: ACPE#: Activity Type: 22 Disclosures
The 99 Mo Supply Chain for Nuclear Medicine
for Nuclear Medicine Department of Electrical and Computer Engineering University of Hartford BE 281 - BE 381 Biomedical Engineering Seminar I and II November 13, 2012 Nuclear Medicine: Meeting Patient
A Supply and Demand Update of the Molybdenum-99 Market
August 2012 A Supply and Demand Update of the Molybdenum-99 Market Introduction Medical diagnostic imaging techniques using technetium-99m account for roughly 80% of all nuclear medicine procedures, representing
The medical isotope crisis
The medical isotope crisis Introduction Last year saw a major worldwide crisis in the availability of medical radioisotopes. More specifically in the production of Mo-99/Tc-99m generators for diagnostic
CORAR Council on Radionuclides and Radiopharmaceuticals, Inc.
RAR Council on Radionuclides and Radiopharmaceuticals, Inc. Understanding the Radiopharmaceutical Drug Supply Problem: Session 1 Michael J. Guastella, MS MBA Executive Director Council on Radionuclides
ENSURING RELIABLE MEDICAL ISOTOPE SUPPLY
ENSURING RELIABLE MEDICAL ISOTOPE SUPPLY Hedges, K. 1, and Malkoske G. 2 1 Atomic Energy of Canada Limited, Mississauga, Ontario, Canada 2 MDS Nordion, Ottawa, Ontario, Canada 1. Introduction This paper
The Economics of Reactor Produced Mo-99
The Economics of Reactor Produced Mo-99 Francois Couillard CANM, April 21, 2017 Disclosures I am a GE shareholder The CAMRT receives funding for Continuing Education and/or its annual conference from Curium,
Australia s unique leadership role
The Global Mo-99 Crisis: s unique leadership role November 09 While most of the world has focused on the global financial crisis, another serious predicament, with enormous ramifications for the world
Staged Introduction of Non-power and Power Nuclear Technologies to Newcomer Countries. Mitsuru Uesaka
November 10, 2016 Third International Conference on Nuclear Knowledge Management: Challenges and Approaches s in Vienna, Austria, from 7 to 11 November 2016 Staged Introduction of Non-power and Power Nuclear
Meeting the moly-99 challenge
Greg Piefer, founder and CEO of SHINE Medical Technologies, aims to begin production of Mo-99 at the company s Janesville, Wis., campus in 2020. Photo: SHINE Meeting the moly-99 challenge In the race to
Global Threat Reduction Initiative
U.S. DEPARTMENT OF ENERGY Global Threat Reduction Initiative Establishing Reliable Supplies of Mo-99 Produced Without HEU Dr. Parrish Staples September 27, 2011 GTRI Mission & Program Goals Convert Remove
Supplying Molybdenum-99 to Global Markets. Kennedy Mang era Chief Operating Officer
Supplying Molybdenum-99 to Global Markets Kennedy Mang era Chief Operating Officer IAEA -Vienna - July 18 th, 2017 CIIC GOALS Leverage our expertise and unique understanding of customer needs to provide
REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the years {SWD(2018) 46 final}
EUROPEAN COMMISSION Brussels, 27.2.2018 COM(2018) 76 final REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT Operation of the High Flux Reactor in the years 2014-15 {SWD(2018) 46 final}
International Perspective on non-heu Mo-99 Production
International Perspective on non-heu Mo-99 Production International Symposium on HEU Minimisation Vienna 23-25 January 2012 Dr Adrian Paterson Michael Druce Australian Nuclear Science and Technology Organisation
High-Level Group on the Security of Supply of Medical Radioisotopes
Unclassified NEA/SEN/HLGMR(2014)2 NEA/SEN/HLGMR(2014)2 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 22-Apr-2014 English
ANSTO Nuclear Medicine: Reliable and Timely Mo-99 Supply Globally
Presentation 8 Session 3 ANSTO Nuclear Medicine: Reliable and Timely Mo-99 Supply Globally Jayne Senior General Manager, ANSTO Nuclear Medicine Pty Ltd (ANM) Biography Jayne Senior is General Manager for
Global Threat Reduction Initiative
U.S. DEPARTMENT OF ENERGY Global Threat Reduction Initiative Implementing the American Medical Isotopes Production Act OSTP Mo-99 Stakeholder s Meeting December 2013 The American Medical Isotopes Production
The "Réacteur Jules Horowitz" : The preliminary design
The "Réacteur Jules Horowitz" : The preliminary design A. BALLAGNY - S. FRACHET CEA Direction des Réacteurs Nucléaires 31, 33 Rue de la Fédération 75752 PARIS Cédex 15 J.L. MINGUET - C. LEYDIER TECHNICATOME
medicine represents more than 20 Billion $ in medical fees 99m Tc are conducted in the world. This not only is
Radio Isotopes (RI) in Nuclear Medicine Nearly 80% of the RI used in nuclear medicine i are produced in nuclear reactors Among these reactor produced RI, the Technetium 99m (6 hrs), a decay product of
Regulatory Experience and Developments Related to Accelerator Isotope Production
Regulatory Experience and Developments Related to Accelerator Isotope Production Abdul Alwani Senior Project Officer Canadian Nuclear Safety Commission WAO 2012 August 6, 2012 Menlo Park, California, USA
Global Threat Reduction Initiative
U.S. DEPARTMENT OF ENERGY Global Threat Reduction Initiative Progress Towards Eliminating Use of Highly Enriched Uranium in Medical Isotope Production and Research and Test Reactor Fuel and Repatriation
On the Practical Use of Lightbridge Thorium-based Fuels for Nuclear Power Generation
On the Practical Use of Lightbridge Thorium-based Fuels for Nuclear Power Generation Revision 1 - July 2010 Lightbridge Corporation 1600 Tysons Blvd. Suite 550 Mclean, VA 22102 USA P +1 571.730.1200 F
Reactor Schedule Coordination for Molybdenum-99 Supply Reliability
Schedule Coordination for Molybdenum-99 Supply Reliability Bernard PONSARD Co-Chairman AIPES Security of Supply Working Group The National Academies NAS-RAS Joint Mo-99 Symposium Opportunities and Approaches
Charles Grant. International Centre for Environmental and Nuclear Sciences University of the West Indies
Charles Grant International Centre for Environmental and Nuclear Sciences University of the West Indies REGIONAL PRACTICAL WORKSHOP ON THE DECOMMISSIONING OF RADIOACTIVELY CONTAMINATED FACILITIES: 22-26
REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT. Operation of the High Flux Reactor in the period
EUROPEAN COMMISSION Brussels, 5.4.2016 COM(2016) 170 final REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT Operation of the High Flux Reactor in the period 2012-2013 {SWD(2016) 101
Supply of Medical Radioisotopes. IPET Vienna October 10, Kevin Charlton Nuclear Development Division OECD/NEA
Supply of Medical Radioisotopes IPET 2015 - Vienna October 10, 2015 Kevin Charlton Nuclear Development Division OECD/NEA Kevin Charlton Senior Analyst - Nuclear Energy Agency (NEA) of the OECD Secretariat
Regulatory Challenges and Solutions High-Enriched to Low-Enriched Uranium Fuel Conversion
Regulatory Challenges and Solutions High-Enriched to Low-Enriched Uranium Fuel Conversion Alexander Adams Jr. Senior Project Manager Research and Test Reactor Program Office of Nuclear Reactor Regulation
World status on reactor and cyclotron radioisotope production
World status on reactor and cyclotron radioisotope production Richard Zimmermann Chrysalium Consulting Mechelen, May 11, 2017 Global trends 2017 Second wave of growth with 177 Lu-Lutathera 2014 The therapeutic
Nuclear Energy Fundamentals
Nuclear Energy Fundamentals PREPARED BY Academic Services April 2012 Institute of Applied Technology, 2012 Module Objectives Upon successful completion of this module, students will be able to: Identify
Status of Mo-99 Supply and New Developments
Status of Mo-99 Supply and New Developments Joao Alberto Osso Junior Head, Radioisotope Products and Radiation Technology Section 06 October 2015 International Atomic Energy Agency The Mandate The Agency
Legislative Framework for the Regulation of Decommissioning at Egypt. Prof. Dr. Farouk M. A. Rahman
Legislative Framework for the Regulation of Decommissioning at Egypt Prof. Dr. Farouk M. A. Rahman Egypt Framework for Decommissioning Legal Decree of the president of the United Arab Republic, law 59
Acceptance and Disposition of Department of Energy Spent Nuclear Fuel
Acceptance and Disposition of Department of Energy Spent Nuclear Fuel Hitesh Nigam Office of Environmental Management Briefing to the National Academy of Sciences December 3, 2014 www.energy.gov/em 1 Outline
DOSE CALCULATION FOR ACCIDENT SITUATIONS AT TRIGA RESEARCH REACTOR USING LEU FUEL TYPE
Romanian Reports in Physics, Vol. 60, No. 1, P. 57 61, 2008 DOSE CALCULATION FOR ACCIDENT SITUATIONS AT TRIGA RESEARCH REACTOR USING LEU FUEL TYPE S. MÃRGEANU 1, C. A. MÃRGEANU 1, C. PÃUNOIU 1, T. ANGELESCU
Nuclear Reactors. 3 Unit Nuclear Power Station - Coastal Bryon Nuclear Plant, Illinois. 3 Unit Nuclear Power Station - Desert
3 Unit Nuclear Power Station - Desert Nuclear Reactors Homeland Security Course February 1, 2007 Tom Gesell 3 Unit Nuclear Power Station - Coastal Bryon Nuclear Plant, Illinois 1 Power Reactor Statistics
Safety and Security of Supply of Medical Isotope Production
Safety and Security of Supply of Medical Isotope Production The Canadian Regulator s Perspective 9th International Conference on Isotopes & Expo Doha, Qatar November 15, 2017 Ramzi Jammal Executive Vice-President
A Network Model and Computational Approach for the 99 Mo Supply Chain for Nuclear Medicine
for the 99 Mo Supply Chain for Nuclear Medicine Ladimer S. Nagurney 1 and Anna Nagurney 2 1 Department of Electrical and Computer Engineering University of Hartford - West Hartford, CT 06117 2 John F.
a Cyclotron based European Multipurpose ADS for R&D (MYRRHA)
a Cyclotron based European Multipurpose ADS for R&D (MYRRHA) Pre-Design Phase Completion H. Aït Abderrahim SCK CEN Boeretang 200, B-2400 Mol, BELGIUM haitabde@sckcen.be p 1 Contents 1. Introduction 2.
SAFETY ANALYSIS AND ASSESSMENT FOR TEMPORARY STORAGE OF 106 IRRADIATED VVR-M2 FUEL TYPE ASSEMBLIES IN DALAT REACTOR
SAFETY ANALYSIS AND ASSESSMENT FOR TEMPORARY STORAGE OF 106 IRRADIATED VVR-M2 FUEL TYPE ASSEMBLIES IN DALAT REACTOR NGUYEN MINH TUAN AND NGUYEN KIEN CUONG Nuclear Research Institute Contents 1. Introduction
ARIEL II: Completion to Science
Canada s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire et en physique des particules ARIEL II: Completion to Science Lia Merminga
Accelerate the Accelerators?! David Nusbaum
Accelerate the Accelerators?! David Nusbaum Research Fellow, Project on Managing the Atom Harvard Kennedy School April 3 rd, 2012 1 Motivation The global stockpile of highly enriched uranium (HEU) was
1. NUCLEAR REACTORS FOR THE PRODUCTION OF MOLYBDENUM-99
CHARACTERISTICS OF NUCLEAR REACTORS USED FOR THE PRODUCTION OF MOLYBDENUM-99 XA9949228 R.M. BALL* Ball Systems Company, Lynchburg, Virginia, United States of America Abstract The paper describes nuclear
Nuclear Research Reactor TRIGA IAN-R1. Jaime Sandoval Lagos Supervisor Reactor Nuclear October 2014
Nuclear Research Reactor TRIGA IAN-R1 Jaime Sandoval Lagos Supervisor Reactor Nuclear October 2014 INTRODUCTION The Nuclear Reactor IAN-R1 went critical on February 1965. It was run by the Instituto de
THE ACCELERATOR PRODUCTION OF TRITIUM PROJECT
THE ACCELERATOR PRODUCTION OF TRITIUM PROJECT P. W. Lisowski, Los Alamos National Laboratory, Los Alamos NM 87545, USA Abstract Tritium is essential for U.S. nuclear weapons to function, but because it
Molten Salt Reactor Technology for Thorium- Fueled Small Reactors
Molten Salt Reactor Technology for Thorium- Fueled Small Reactors Dr. Jess C. Gehin Senior Nuclear R&D Manager Reactor and Nuclear Systems Division gehinjc@ornl.gov, 865-576-5093 Advanced SMR Technology
JORDAN RESEARCH AND TRAINING REACTOR UTILIZATION FACILITIES
JORDAN RESEARCH AND TRAINING REACTOR UTILIZATION FACILITIES NED XOUBI Jordan Atomic Energy Commission (JAEC), Amman, Jordan Ned@Xoubi.com 1. INTRODUCTION The building and construction of a research and
OPAL. Australia s Research Reactor. Greg Storr
OPAL Australia s Research Reactor Greg Storr OPAL Sydney ANSTO Site Research reactor operation OPAL replaced HIFAR IAEA Centre of Excellence for neutron beam science Radio-isotopes for medicine, research
Department of Energy Spent Nuclear Fuel - Update. Outline
Department of Energy Spent Nuclear Fuel - Update Edgard Espinosa Office of Environmental Management Briefing to the Institute for Nuclear Materials Management January 13, 2015 www.energy.gov/em 1 Outline
Present Status of Kyoto University Research Reactor, KUR
18th IGORR conference/iaea Technical Meeting 3-7 Dec. 2017, Sydney, Australia Present Status of Kyoto University Research Reactor, KUR Ken NAKAJIMA Research Reactor Institute, Kyoto University 1 Accident
Perma-Fix Medical. Investor Presentation January 2016
Perma-Fix Medical Investor Presentation January 2016 1 Safe Harbor Certain statements contained within this presentation may be deemed forward-looking statements within the meaning of Section 27A of the
COMPARATIVE STUDY OF TRANSIENT ANALYSIS OF PAKISTAN RESEARCH REACTOR-1 (PARR-1) WITH HIGH DENSITY FUEL
COMPARATIVE STUDY OF TRANSIENT ANALYSIS OF PAKISTAN RESEARCH REACTOR-1 (PARR-1) WITH HIGH DENSITY FUEL M. Iqbal, A. Muhammad, T. Mahmood Nuclear Engineering Division, Pakistan Institute of Nuclear Science
Lecture (3) on. Nuclear Reactors. By Dr. Emad M. Saad. Mechanical Engineering Dept. Faculty of Engineering. Fayoum University
1 Lecture (3) on Nuclear Reactors By Dr. Emad M. Saad Mechanical Engineering Dept. Faculty of Engineering Fayoum University Faculty of Engineering Mechanical Engineering Dept. 2015-2016 2 Nuclear Fission
6/6 Zoom out from centre. 8/14 Pan right zoom in bottom right 10/24 Zoom in center
Narrative 1. Canada s first involvement in nuclear activity was a partnership with Britain and the United States during World War 2 Time (secs) / elapsed Start Image End Image Motion 6/6 Zoom centre 2.
Working Group 4 (WG4) Capacity and Infrastructure Development. July, 2014
Working Group 4 (WG4) Capacity and Infrastructure Development July, 2014 1. Overview Radionuclides are used in nuclear medicine for the diagnosis and treatment of various diseases, such as cancer, cardiovascular
Structural Concerns with the Global Nuclear Fuel Industry May 31,
Structural Concerns with the Global Nuclear Fuel Industry May 31, 2012 www.thorium1.com Overview Steps in the nuclear fuel cycle Supply factors Demand factors US nuclear sector Problems with the Fuel Cycle
Examples of Research Reactor Conversion Assessment of Alternatives
Examples of Research Reactor Conversion Assessment of Alternatives Benoit Dionne, Ph.D. Section Manager - Conversion Analysis and Methods Nuclear Engineering Division, Argonne National Laboratory National
Safety Analysis of the MIT Nuclear Reactor for Conversion to LEU Fuel
Global Threat Reduction Initiative Safety Analysis of the MIT Nuclear Reactor for Conversion to LEU Fuel Erik H. Wilson, Floyd E. Dunn Argonne National Laboratory Thomas H. Newton Jr., Lin-wen Hu MIT Nuclear
Unique Irradiation Rigs developed for the HFR Petten at the JRC-IE;
Unique Irradiation Rigs developed for the HFR Petten at the JRC-IE; details of LYRA, QUATTRO and Fuel Irradiation facilities JRC-IE, Institute For Energy, Petten L.Debarberis, B. Acosta, J.Degmova, A.Zeman,
Science of Nuclear Energy and Radiation
CNS Science of Nuclear Energy and Radiation Ben Rouben 1998 June page 1 The Nuclear Fuel Cycle Ben Rouben Manager, Reactor Core Physics AECL page 2 Topic of Discussion Nuclear fuel cycle. Will cover various
The Threat Posed by HEU, and Legislation to Reduce Bomb- Grade Uranium Commerce
The Threat Posed by HEU, and Legislation to Reduce Bomb- Grade Uranium Commerce Alan J. Kuperman, Ph.D. Associate Professor, LBJ School of Public Affairs; and Director, Nuclear Proliferation Prevention
THE ROLE OF A RESEARCH REACTOR IN THE NATIONAL NUCLEAR ENERGY PROGRAMME IN VIETNAM: PRESENT AND FUTURE
C10 THE ROLE OF A RESEARCH REACTOR IN THE NATIONAL NUCLEAR ENERGY PROGRAMME IN VIETNAM: PRESENT AND FUTURE K.C. NGUYEN, T.N. HUYNH, V.V. LE, B.V. LUONG Reactor Center, Nuclear Research Institute, Vietnam
Safeguards at research reactors: Current practices, future directions
Safeguards at research reactors: Current practices, future directions Some new verification measures are being introduced to improve the efficiency and the effectiveness of the Agency's safeguards by Giancarlo
Multivariate Optimization of High Brightness High Current DC Photoinjector. Ivan Bazarov, Cornell University
Multivariate Optimization of High Brightness High Current DC Photoinjector Ivan Bazarov, Cornell University Talk Outline: ERL DC Gun Injector Evolutionary Algorithms Optimization Results I.V. Bazarov,
Sustaining Material Testing Capacity in France: From OSIRIS to JHR
Sustaining Material Testing Capacity in France: From OSIRIS to JHR to support industry and public organizations in R&D irradiation programs on nuclear fuel and materials Stéphanie MARTIN, French Alternative
Multipurpose Research Reactor (RMB) Project Status. José Augusto Perrotta CNEN - Brazil
Multipurpose Research Reactor (RMB) Project Status José Augusto Perrotta CNEN - Brazil November 2011 Research Reactors in Brazil Name Utilization Power Location Startup Type IEA-R1 Research Radioisotope
NIIEFA Accelerators for Industry and Medicine
FSUE D.V. Efremov Scientific Research Institute of Electrophysical Apparatus ( NIIEFA ) Saint-Petersburg,, Russia NIIEFA Accelerators for Industry and Medicine M.F. Vorogushin vorogushin@luts.niiefa.spb.su
IAEA assistance in RI production and supply: 99 Mo case
IAEA assistance in RI production and supply: 99 Mo case Joao Alberto Osso Junior Head, Radioisotope Products and Radiation Technology Section NAPC/NA/IAEA The IAEA Mandate The Agency shall seek to accelerate
KIPT ACCELERATOR DRIVEN SYSTEM DESIGN AND PERFORMANCE
KIPT ACCELERATOR DRIVEN SYSTEM DESIGN AND PERFORMANCE Yousry Gohar 1, Igor Bolshinsky 2, Ivan Karnaukhov 3 1 Argonne National Laboratory, USA 2 Idaho National Laboratory, USA 3 Kharkov Institute of Physics
IAEA SUPPORT ACTIVITIES FOR RESEARCH REACTORS
SUPPORT ACTIVITIES FOR RESEARCH REACTORS Andrea Borio di Tigliole (A.Borio@iaea.org) Department of Nuclear Energy Division of Nuclear Fuel Cycle and Waste Technology Research Reactor Section International
Illinois Accelerator Research Center
FERMILAB-CONF-16-639-AD-DI ACCEPTED Conference on the Application of Accelerators in Research and Industry, CAARI 2016, 30 October 4 November 2016, Ft. Worth, TX, USA Illinois Accelerator Research Center
Burn up Analysis for Fuel Assembly Unit in a Pressurized Heavy Water CANDU Reactor
Burn up Analysis for Fuel Assembly Unit in a Pressurized Heavy Water CANDU Reactor A. A. EL-Khawlani a, Moustafa Aziz b, M. Ismail c and A. Y. Ellithi c a Physics Department, Faculty of Science, High Education,
Isotope Production at LERF
Isotope Production at LERF Andrew Hutton Jefferson Lab for Hari Areti, Pavel Degtiarenko, Joe Gubeli, Kevin Jordan, George Kharashvili, George Neil Jefferson Lab Sundaresan Gobalakrishnan, Jamal Zweit
Incentivizing Domestic Production of Molybdenum-99 for Diagnostic Medicine
Incentivizing Domestic Production of Molybdenum-99 for Diagnostic Medicine Logan Michael Scott American Nuclear Society Oklahoma State University August 2013 ii Executive Summary With about thirty-eight
Thorium an alternative nuclear fuel cycle
Thorium an alternative nuclear fuel cycle 5th Smart Grids & Clean Power Conference, Cambridge, 5 June 2013 www.cir-strategy.com/events/cleanpower Kevin Hesketh, Senior Research Fellow Outline General Principles
LEU Conversion of the University of Wisconsin Nuclear Reactor
LEU Conversion of the University of Wisconsin Nuclear Reactor Paul Wilson U. Wisconsin-Madison Russian-American Symposium on the Conversion of Research Reactors to Low Enriched Uranium Fuel 8-10 June 2011
The Critical Need for Nuclear Medicine Radioisotopes and Research
The Critical Need for Nuclear Medicine Radioisotopes and Research University of Missouri Research Reactor Center s Radioisotope Production and BNCT Research 13 October 2009 University of Missouri A Unique
UTILIZATION OF ETRR-2 AND COLLABORATION 1. INTRODUCTION
UTILIZATION OF ETRR-2 AND COLLABORATION M.K. SHAAT Nuclear Energy Centre, Egypt s Atomic Energy Authority (EAEA), Cairo, Egypt m_shaat30@hotmail.com 1. INTRODUCTION Owners and operators of many research
AREVA Back-End Possibilities for the Used Fuel of Research Test Reactors
AREVA Back-End Possibilities for the Used Fuel of Research Test Reactors P. Auziere, J.L. Emin, T. Louvet AREVA, COGEMA, 2 rue Paul Dautier, BP 4, 78 141 Vélizy Cédex, France D. Ohayon, AREVA (COGEMA LOGISTICS),
Status of the FRM-II Project at Garching. Hans-Jürgen Didier, Gunter Wierheim Siemens AG, Power Generation (KWU), D Erlangen
IGORR7 7 th Meeting of the International Group on Research Reactors October 26-29, 1999 Bariloche, Argentina Status of the FRM-II Project at Garching Hans-Jürgen Didier, Gunter Wierheim Siemens AG, Power
DECOMMISSIONING OF THE IFIN-HH VVR-S NUCLEAR RESEARCH REACTOR Dr. Mitica Dragusin, IFIN-HH, Romania
DECOMMISSIONING OF THE IFIN-HH VVR-S NUCLEAR RESEARCH REACTOR Dr. Mitica Dragusin, IFIN-HH, Romania I. Introduction IFIN-HH institute administrates with the diligence of a good owner the principal public
Nuclear Energy Revision Sheet
Nuclear Energy Revision Sheet Question I Identify the NPP parts by writing the number of the correct power plant part in the blank. Select your answers from the list provided below. 1 Reactor 2 Steam generator
PALLAS A nuclear reactor
PALLAS A nuclear reactor fit for the future! IAEA Headquarters, Vienna, Austria 16 May 2011 Ir. Paul G.T. de Jong, Project Director PALLAS 1 Let s introduce myself Paul de Jong, degree in Physics of the
Jamison Reifsteck and Even Lydon. Sustainable and Renewable Energy. Dr. Beck Thorium
Jamison Reifsteck and Even Lydon Sustainable and Renewable Energy Dr. Beck 03-25-2017 Thorium Recently, Thorium has reemerged as a powerful potential energy source. Thorium has a lot of the benefits of
The Nuclear Fuel Cycle Lecture 5
The Nuclear Fuel Cycle Lecture 5 David J. Hamilton d.hamilton@physics.gla.ac.uk 7th February 2011 1. Overview Limitations of thermal recycling of Pu. Fast critical reactors: core physics; breeders; transmutation.
WM2012 Conference, February 26 March 1, 2012, Phoenix, Arizona, USA. Opportunities for the Multi Recycling of Used MOX Fuel in the US
Opportunities for the Multi Recycling of Used MOX Fuel in the US - 12122 P. Murray*, F. Bailly**, E. Bouvier**, T. Gain**, F. Lelièvre**, G.H. Senentz**, and E. Collins*** *AREVA Federal Services LLC,
A Clean, Secure Nuclear Energy Solution for the 21 st Century Advanced Reactor Concepts, LLC (ARC) June 2010
A Clean, Secure Nuclear Energy Solution for the 21 st Century Advanced Reactor Concepts, LLC (ARC) June 2010 Introduction As the world grapples with the energy requirements of the future, and the associated
DEVELOPMENT OF EDUCATION AND TRAINING PROGRAMS USING ISIS RESEARCH REACTOR
A5 DEVELOPMENT OF EDUCATION AND TRAINING PROGRAMS USING ISIS RESEARCH REACTOR F. FOULON, B. LESCOP National Institute for Nuclear Science and Technology, CEA, Saclay Research Center, Gif-sur-Yvette, France
IAEA Technical Meeting on Products and Services of Research Reactors 28 June 2 July 2010 IAEA, Vienna, Austria
IAEA Technical Meeting on Products and Services of Research Reactors 28 June 2 July 2010 IAEA, Vienna, Austria Shaat.M.K..doc, ETRR-2 Reactor, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt e-mail:
KIPT ADS Facility. Yousry Gohar 1, Igor Bolshinsky 2, Ivan Karnaukhov 3. Argonne National Laboratory, USA 2. Idaho National Laboratory, USA 3
KIPT ADS Facility Yousry Gohar 1, Igor Bolshinsky 2, Ivan Karnaukhov 3 1 Argonne National Laboratory, USA 2 Idaho National Laboratory, USA 3 Kharkov Institute of Physics & Technology, Ukraine EuCARD 2
MCNP5 CALCULATIONS COMPARED TO EXPERIMENTAL MEASUREMENTS IN CEA-MINERVE REACTOR
U.P.B. Sci. Bull., Series D, Vol. 74, Iss. 1, 2012 ISSN 1454-2358 MCNP5 CALCULATIONS COMPARED TO EXPERIMENTAL MEASUREMENTS IN CEA-MINERVE REACTOR Mirea MLADIN 1, Daniela MLADIN 21 The paper describes the
Temperature Rise in LCLS-II Cavity Bellows
Temperature Rise in LCLS-II Cavity Bellows LCLS-II TN-15-06-9-015 Arun Saini, Nikolay Solyak, V. Yakovlev, A. Sukhanov, A. Lunin July 30, 015 LCLSII-TN-XXXX Abstract Studies are performed to evaluate temperature
The new material irradiation infrastructure at the BR2 reactor. Copyright 2017 SCK CEN
The new material irradiation infrastructure at the BR2 reactor The new material irradiation infrastructure at the BR2 reactor Steven Van Dyck, Patrice Jacquet svdyck@sckcen.be Characteristics of the BR2
THE ROLE OF REGULATORY AUTHORITY IN SAFE OPERATION OF RESEARCH REACTOR
THE ROLE OF REGULATORY AUTHORITY IN SAFE OPERATION OF RESEARCH REACTOR International Conference on Research Reactor Safe Management and Effective Utilization Sydney (Australia), 5 9 November 27 Contents:.
Experimental Potentialities of the MBIR Reactor
International Conference on Fast Reactors and Related Fuel Cycles: Safe Technologies and Sustainable Scenarios (). Paris, France, 4-7 March 2013 Experimental Potentialities of the MBIR Reactor Based on
Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons
Cyclotron & Medical Isotopes Best Theratronics announces plans to address the medical isotope shortage by manufacturing a range of cyclotrons Ottawa, Ontario, Canada 1 March 2012 Richard Johnson, Ph.D.
Medical isotope production in Australia:
Medical isotope production in Australia: Should we be using reactor based or cyclotron technology? 15 th January 2016 Dr Margaret Beavis MBBS FRACGP MPH Medical Association for Prevention of War, Australia
NOVEL UTILIZATION OF TRIGA REACTORS
Preliminary Safety Analysis Report (PSAR): NOVEL UTILIZATION OF TRIGA REACTORS FOR ISOTOPE PRODUCTION (NUTRIP) MO- 99 PRODUCTION USING TRIGA REACTORS NE 267: Nuclear Reactor Safety Professor Per F. Peterson
Neutronics Simulations of 237 Np Targets to Support Safety-Basis and 238 Pu Production Assessment Efforts at the High Flux Isotope Reactor
Neutronics Simulations of 237 Np Targets to Support Safety-Basis and 238 Pu Production Assessment Efforts at the High Flux Isotope Reactor David Chandler and R. J. Ellis chandlerd@ornl.gov Oak Ridge National